**Core Concept**
The question is testing the understanding of enzyme kinetics, specifically the effect of a drug on enzyme activity. The patient's symptoms suggest myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and fatigue, which can be treated with anticholinesterase inhibitors. The kinetic analysis is likely showing a change in the enzyme's activity in response to the medication.

**Why the Correct Answer is Right**
The kinetic analysis shows a decrease in the Km (Michaelis constant) and an increase in Vmax (maximum velocity) in the presence of the drug. This is characteristic of a non-competitive inhibitor, which binds to a site on the enzyme other than the active site, causing a conformational change that increases the enzyme's affinity for the substrate (decreased Km) and also increases the enzyme's activity (increased Vmax). In the context of myasthenia gravis, the drug is likely an anticholinesterase inhibitor, such as pyridostigmine, which increases the concentration of acetylcholine in the synaptic cleft by inhibiting the enzyme acetylcholinesterase.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because a competitive inhibitor would decrease Vmax and increase Km, which is not consistent with the kinetic analysis.
**Option B:** This option is incorrect because a non-competitive inhibitor would decrease Vmax, but Km would remain unchanged.
**Option C:** This option is incorrect because an uncompetitive inhibitor would decrease Vmax and decrease Km, which is not consistent with the kinetic analysis.

**Clinical Pearl / High-Yield Fact**
When interpreting enzyme kinetic data, remember that a decrease in Km suggests an increase in enzyme affinity for the substrate, while an increase in Vmax suggests an increase in enzyme activity.

**Correct Answer:** C.

✓ Correct Answer: A. Type of Inhibition - Competitive; Effect on Km (as Compared to No Drug) - Increased; Effect of Vmax(as compared to No drug - No change